Anticoagulants antiplatelets fibrinolytics Flashcards
(107 cards)
1
Q
Steps of normal hemostasis
A
Vasospasm (reduce blood flow and enhance platelet aggregation+coagulation). Formation of platelet plug. Thombin catalyzes fibrinogen to fibrin. Fibrin clot formation. Fibrinolysis by plasmin.
2
Q
When are the different coagulation pathways activated?
A
Intrinsic pathway: surface contact with a foreign body or extravascular tissue.
Extrinsic pathway: Thromboplastin
3
Q
Coagulation factors that are dependent on vitamin K
A
II - prothrombin.
VII - proconvertin (no longer considered a coagulation factor).
IX - plasma thromboplastin component.
X - Stuart factor.
4
Q
Major rate limiting step in coagulation cascade
A
Activation of factor X
5
Q
Thrombin - effects
A
Catalyzes fibrinogen to fibrin, and is a powerful stimulus for platelet aggregation.
6
Q
Stimulus for platelet aggregation and coagulation
A
Atherosclerosis, venous pooling, thrombophlebitis
7
Q
White vs red thrombi - location and mechanism
A
White thrombi: arterial circulation - often caused bu platelet aggregation.
Red thrombi: venous ciculation - often caused bu coagulation.
8
Q
Main types of anticoagulants
A
Vitamin K antagonists.
Drugs that potentiate antithrombin III.
Drug that directly inhibit thrombin or active factor X.
9
Q
Which coagulation factors are inhibited by warfarin, and in which pathway are these factors found?
A
IX - intrinsic VII - extrinsic X - both pathways Prothrombin - both pathways (all are inactive factors)
10
Q
Which coagulation factors are inhibited by heparin?
A
All active coagulation factors
11
Q
Intrinsic coagulation pathway - cascade
A
1) Surface contact
2) XII (Hageman factor) activation
3) XI activation
4) IX activation
5) X (Stuart factor) activation
6) II (prothrombin) activation.
7) activation of fibrin, and formation of stabilized fibrin by factor XIII
12
Q
Extrinsic coagulation pathway - cascade
A
1) Tissue factor.
2) VII (proconvertin) activation
3) Activation of X (Stuart factor)
4) II (prothrombin) activation.
5) activation of fibrin, and formation of stabilized fibrin by factor XIII
13
Q
Drugs that may increase prothrombin time (15 drugs)
mnemonic, letter for each drug) ADD CAMP CHARTS FA(st
A
Amiodarone Cimetidine Disulfiram Fluconazole Metronidazole Phenylbutazone Sulfinpyrazone Trimethoprim-sulfamethoxazole Aspirin (high doses) Cephalosporins, third-generation Heparin, argatroban, dabigatran, rivaroxaban, apixaban
14
Q
Body factors that may increase prothrombin time
A
Hyperthyroidism, hepatic disease
15
Q
Drugs that may decrease prothrombin time
A
Barbiturates Cholestyramine Rifampin Diuretics Vit K
16
Q
Body factors that may decrease prothrombin time
A
Hereditary resistance, hypothyroidism
17
Q
Anticoagulants - 3 groups
A
Vitamin K antagonists.
Drugs that potentiate antithrombin III (AT-III).
Direct thrombin inhibitors
18
Q
Vitamin K antagonists - 1 drug
A
Warfarin
19
Q
Warfarin - classification
A
Vitamin K antagonist, coumarin compound.
20
Q
Warfarin - MOA
A
Inhibit the reduction of oxidized vit K, which blocks posttranslational carboxylation of factors II (prothrombin), VII, IX and X, and these factors cannot be synthesized.
Also inhibits proteins C and S (may cause transient procoagulant effect).
21
Q
Protein C and S - function
A
Endogenous anticoagulants that inactivate factors V and VIII and promote fibrinolysis.
22
Q
Warfarin - contraindications
A
Pregnancy (crosses placenta and may cause fetal warfarin syndrome - fetal hemorrhage and birth defects).
Starting/discontinuing other drugs: must be evaluated by physician because of interactions.
23
Q
Warfarin - onset of action
A
Delayed 3-5 days because of the time it takes to deplete the pool of circulating clotting factors.
24
Q
How should chronic treatment for thromboembolic disorders be started?
A
Low-molecular-weight heparin and warfarin. When warfarin has started working, heparin is discontinued.
25
Adverse effets of warfarin
Bleeding (pts should report hematuria and ecchymoses)
26
Fetal warfarin syndrome - symptoms
Chondrodysplasia puncta, malformation of ears & eyes, mental retardation, nasal hypoplasia, optic atrophy, skeletal deformities, hemorrhage)
27
Why does warfarin cause fetal deformities?
Antagonizes vit K-dependent maturation of bone proteins.
28
Interactions of warfarin (direct increasers of prothrombin time, inducing CYP enzymes, and inhibit absorption)
Direct reduction of prothrombin levels: High dose of salicylates. Some 3rd generation cephalosporins.
Induce CYP enzymes: rifampin and barbiturates.
Inhibit absorption: Cholestyramine
29
Interactions of warfarin (drugs that inhibit CYP enzymes)
Amiodarone, cimetidine, erythromycin, fluconazole, gemfibrozil, isoniazid, metronidazole, sulfinpyrazone.
30
Treatment of warfarin-associated hemorrhage
Withdraw/reduce dose of warfarin. Phytonadione (vitamin K1) - direct antagonism of warfarin.
Severe: (INR>20) fresh plasma or factor IX concentrate
31
Warfarin - indications
Long-term treatments. DVT, AF, artificial heart valve. MI with heparin.
32
How to measure the effect of warfarin?
PT (1.3-1.5 times control PT)
| INR (observedPT/controlPT): 2-3 (3-4.5 mechanical prosthetic valves and recurrent embolization)
33
Heparins - 2 drugs + 1 group
Unfractionated hepatin
Low-molecular-weight heparins (LMWHs)
Fondaparinux
34
LMWHs (3 drugs)
Enoxaparin
Dalteparin
Tinzaparin
35
Heparins - MOA
Inactivates clotting factors by potentiating antithrombin III
36
AT-III - functions
Most potent endogenous inhibitor of active factor X (Stuart factor) and II (thrombin).
37
LMWHs - MOA
Primarily inactivation of factor X (LMWH-AT-III complex has less affinity for thrombin than heparin-AT-III complex)
38
Heparin - adm
Parenterally, usually continuous IV infusion
39
How is the effect of heparin determined?
aPPT (activated partial thromboplastin time) - 1.5-2 times normal is adequate dosing. Not needed for LMWHs
40
LMWHs - adm
Subcutaneously
41
Heparins - adverse effects
Bleeding.
Heparin-induced thrombocytopenia (HIT) type I & type 2
Hyperkalemia (because of suppression of aldosterone secretion)
42
Type 1 HIT - mechanism and what should be done
Direct interaction between heparin and platelets that lead to a usually mild platelet aggregation. Reversible within 4 days despite continued heparin treatment.
25 % of pts.
43
Type 2 HIT - mechanism and what should be done
Immunoglobulin-mediated platelet inactivation with high risk of thrombotic complications. The drug must be discontinued.
44
Heparin - indications
Acute thromboembolic disorders: peripheral and pulmonary embolisms, venous thrombosis, coagulopathies (e.g. DIC)
Prophylaxis: Arterial and heart surgeries, blood transfusions, renal dialysis, blood sample collection, acute atrial fibrillation.
Low doses for prevention of DVT/pulmonary embolism in high-risk pts.
45
LMWHs - indications
Prevent venous thromboembolism after abdominal surgery and hip/knee replacements.
Unstable angina & non-ST-segment elevation MI, acute coronary syndrome, angioplasty
46
Enoxaparin - indications
Prevent DVT in severely immobilized pts.
47
Fondaparinux - adm and indications
Subcutaneous adm for DVT prophylaxis after hip fracture or hip/knee-replacements
48
Hemorrhage by heparin - treatment and adm
Protamine sulfate - combines with heparin and inactivates it. Adm IV.
Severe bleeding: fresh plasma or clotting factors
49
Direct thrombin inhibitors - groups/drugs and adm
Hirudin derivatives - parenterally (IV)
| Dabigatran - orally
50
Hirudin derivatives
Hirudin
Lepirudin
Bivalirudin
Argatroban
51
Hirdurin derivatives - adverse effects
Bleeding
| Do not cause thrombocytopenia
52
Lepirudin - indications
Replace heparin after HIT.
53
Hirudin derivatives - indiactions
Prevent thrombosis in unstable angina, acute MI, stent insertions and coronary angioplasty.
54
Argatroban - indications
Prophylaxis and treatment of thrombosis in pts with HIT.
| Pts undergoing percutaneous coronary interventions for MI.
55
Dabigatran - interactions
```
Few interactions with drugs and food.
Renal impairment decreases elimination (reduce dose).
The drug (bot not the active metabolite) is a substrate for P-glycoprotein (Pgp) transporter --> contraindicated with rifampin (inducer of Pgp transporter.
```
56
Dabigatran - MOA
Potent, competitive and reversible inhibition of thrombin.
57
How can the effect of dabigatran be monitored?
Thrombin clotting time (TT). However, monitoring is not usually necessary.
58
Dabigatran - indications
Nonvalvular atrial fibrillation (reduce risk of stroke and embolism).
Hip/knee replacements - prevent thromotic complications.
59
Dabigatran - adverse effects
Bleeding.
| Dyspepsia, gastritis-like symptoms (reduced with food or H2 blocker).
60
Hemorrhage associated with dabigatran - treatment
There is no antidote. Give plasma or RBCs.
61
Active factor X inhibitors - 2 drugs
Apixaban
| Rivaroxaban
62
Rivaroxaban - indications
Hip/knee replacement: prevent DVT, blood clots, pulmonary embolism
63
Rivaroxaban - interactions
Metabolized by P450 isoenzymes (esp 3A4).
| Increased levels bu Pgp transporter inhibitor.
64
Rivaroxaban - adverse effects
Bleeding
| Careful in pregnancy.
65
Apixaban - indications
Atrial fibrillation when warfarin cannot be used.
| Prevent venous thromboembolism and cardiovascular events in MI.
66
Rivaroxaban, Apixaban, Endoxaban - antidote
Andexanet alfa (AndexXa). Dosing for the initial bolus and subsequent infusion depend on the dose level of the factor Xa inhibitor and the interval since it was last taken.
-OR-
4-factor PCC (Kcentra, Beriplex P/N, Octaplex). Dosing can be done with a fixed dose of 2000 units OR a weight-based dose of 25 to 50 units per kg.
Active factor VII
67
Dabigatran(Pradaxa) reversal agent
Idarucizumab (Praxbind). Dose: 5 grams*
68
Aspirin - MOA of antiplatelet effect
In low doses aspirin selectively inhibits thromboxane A2 (TXA2) synthesis (promotes aggregation). Prostacyclin (platelet aggregation inhibiting) inhibition: higher doses.
Irreversible inhibition of COX.
69
Aspirin - indications
Ischemic heart disease & stroke: Secondary prevention.
Angina: prevent MI
Primary prevention: men>45, women>55 with risk factors for heart disease/stroke (diabetes).
Acute MI, TIA (prevent stroke), artificial heart valves, percutaneous coronary angioplasty.
Peripheral occlusive disease, chronic limb ischemia.
70
Aspirin - adverse effects
Bleeding (esp GI, inhibition of prostaglandins = inhibition of bicarbonate & mucus secretion).
High doses: hypoprothrombinemia
71
Antiplatelet drugs - 3 drugs, 2 groups
```
Aspirin
Dipyridamole
Cilostazol
ADP inhibitors
Glycoprotein IIb/IIIa antagonists
```
72
Dipyridamole - MOA
Coronary vasodilator and weak antiplatelet.
Inhibits platelet adhesion to the vessel wall, and platelet aggregation (latter by increasing cAMP and decreasing Ca in platelets)
73
Dipyridamole - indications
Vasodilation: myocardial perfusion imaging (thallium imaging).
Antiplatelet: with aspirin for prevention of ischemic (thrombotic) stroke in pts who had this or have TIA.
74
Cilostazol - MOA
Inhibits phosphodiesterase III and increase cAMP in platelets & blood vessels. This causes vasodilation and inhibition of platelet aggregation
75
Cilostazol - Indications
Intermittent claudication (limb weakness & pain)
76
Cilostazol - interactions
Metabolized by CYP3A4 (e.g. erythromycin may increase antiplatelet effect)
77
ADP inhibitors - 4 drugs
Clopidogrel
Prasugrel
Ticlopidine
Ticagrelor
78
ADP inhibitors - interactions
Ticlopidine, clopidogrel, prasugrel: metabolized into active metabolite by CYPs.
Clopidogrel: activation is potentially inhibited by PPI (but they can be given together).
Ticagrelor does not need activation.
79
Which ADP inhibitor has greater potency?
Prasugrel
80
ADP inhibitors - MOA
Clopidogrel requires in vivo biotransformation to an active thiol metabolite. The active metabolite irreversibly blocks the P2Y12 component of ADP receptors on the platelet surface, which prevents activation of the GPIIb/IIIa receptor complex, thereby reducing platelet aggregation. Platelets blocked by clopidogrel are affected for the remainder of their lifespan (~7 to 10 day)
Clopidogrel, ticlopidine, prasugrel: irreversible antagonists
Ticagrelor - reversible antagonists.
81
When is ticagrelor better to use than other ADP-inhibitors
E.g. surgery - when irreversible inhibition is not needed.
82
Clopidogrel & prasugrel - indications
Pts who cannot take aspirin: Prevent thrombotic stroke.
With aspirin: ACS.
Clopidogrel also in: Intermittent claudication of blood vessels, chronic arterial occlusion, atrioventricular shunts/fistulas, open heart surgery, sickle cell anemia.
83
Ticagrelor - indications
Prevention of thrombotic events in MI or STEMI (with aspirin unless contraindicated).
84
Ticagrelor - adverse effects
Dyspnea
85
Ticlopidine - adverse effects
Severe neutropenia (complete blood count evr 2 weeks).
86
Glycoprotein IIb/IIIa antagonists - 3 drugs
Abciximab
Tirofiban
Eptifibatide
87
GP IIb/IIIa antagonists - MOA
Binds to platelet GP IIb/IIIa reveptors and prevents fibrinogen to bind and crosslinking of platelets.
Tirofiban and eptifibatide: competitive, reversible inhibitors.
88
Abciximab - indications
Combo with aspirin and heparin/LMWHs: Percutaneous coronary interventions (coronary angioplasty, stent placement).
Adjunct to thrombolysis
89
Abciximab - adverse effects
Bleeding, thrombocytopenia, hypotension, bradycardia.
90
Tirofiban and eptifibatide - indications
Unstable angina and MI (often combo with LMWHs).
| Eptifibatide - STEMI, coronary angioplasty/stent placement
91
Aspirin - interactions
Sulfonylureas: increased hypoglycemic effect.
Methotrexate, valproate: increased GI bleeding+ ulceration.
Probenecid: inhibits uricosuric effect.
92
Fibrinolytic drugs 1 group and 3 drugs
Recombinant tissue plasminogen activators (t-PA)
Urokinase
Streptokinase
Anistreplase
93
Fibrinolytic drugs - indications
Degrade thrombus in MI, thrombotic stroke, pulmonary embolism.
94
t-PAs - 3 drugs
Alteplase
Reteplase
Tenecteplase
95
Fibrinolytic drugs - MOA
Convert plasminogen to plasmin.
96
Fibrinolytic drugs - adverse effects
Bleeding, but less with t-PAs.
Arrhythmias (tachy and brady) --> from free radicals after reperfusion of coronary arteries after thrombolysis.
Streptokinase - hypersensitivity (anaphylactic shock), should not be used repeatedly in same pt.
97
Treatment of fibrinolytic drug-associated hemorrhage
Aminocaproic acid - inhibits fibrinolysis.
98
Aminocaproic acid - indications
Hemorrhage by fibrinolytic drugs.
After GI or prostate surgery.
Cancer pts during radiation/chemo.
99
Aminocaproic acid - amd
Orally or intravenously
100
Aminocaproic acid - adverse effects
Thrombosis, hypotension, arrhythmias.
101
Tranexamic acid - what is it, and MOA.
Antifibrinolytic drug. Occupies the lysine binding sites of plasmin for fibrin.
102
Tranexamic acid - indications
Heavy menstrual bleedings.
103
Tansexamic acid - adverse effects
Thrombotic events (esp if pts are on hormonal contraceptives, are obese or smoking).
104
Fibrinolytic drugs that may be given by infusion
Streptokinase, alteplase
105
Fibrinolytic drugs that may be given in bolus
Reteplase
| Tenecteplase
106
Systemic fibrinogen depletion of fibrinolytic drugs
Streptokinase: marked
Reteplase: moderate
Alteplase: mild
Tenecteplase: minimal.
107
Contraindications to thrombolysis
Contraindications to fibrinolytic therapy for deep venous thrombosis or acute pulmonary embolism
Absolute contraindications
Prior intracranial hemorrhage
Known structural cerebral vascular lesion
Known malignant intracranial neoplasm
Ischemic stroke within three months (excluding stroke within three hours*)
Suspected aortic dissection
Active bleeding or bleeding diathesis (excluding menses)
Significant closed-head trauma or facial trauma within three months
Relative contraindications
History of chronic, severe, poorly controlled hypertension
Severe uncontrolled hypertension on presentation (SBP >180 mmHg or DBP >110 mmHg)
History of ischemic stroke more than three months prior
Traumatic or prolonged (>10 minute) CPR or major surgery less than three weeks
Recent (within two to four weeks) internal bleeding
Noncompressible vascular punctures
Recent invasive procedure
For streptokinase/anistreplase - Prior exposure (more than five days ago) or prior allergic reaction to these agents
Pregnancy
Active peptic ulcer
Pericarditis or pericardial fluid
Current use of anticoagulant (eg, warfarin sodium) that has produced an elevated international normalized ratio (INR) >1.7 or prothrombin time (PT) >15 seconds
Age >75 years
Diabetic retinopathy
